Renalytix (RNLX) said Thursday it has submitted a request for a hearing with Nasdaq to present a plan to regain compliance with the stock market's listing requirements.
The company said it has been notified that it has been out of compliance with Nasdaq minimum closing share price and market value requirements.
The hearing request automatically stays any suspension or delisting procedures, and the company's American Depositary Shares will continue trading on Nasdaq.